苏州吉美瑞生医学科技有限公司

Suzhou Jimray Biotechnology Co., Ltd. is pioneering the future of regenerative medicine with its flagship product, REGEND001 cell preparation, the world's first autologous stem cell solution for respiratory diseases. Established in 2015, the company has received approval from the State Food and Drug Administration and is registered by both the National Health and Family Planning Commission and the Food and Drug Administration for clinical stem cell research. The firm has also garnered support from the Ministry of Science and Technology for its key research and development programs. With ISO9001:2008 quality management system certification and various accreditations, Suzhou Jimray Biotechnology is devoted to adhering to stringent regulatory standards. The company's visionary approach has attracted a CNY100.00M Series B investment on March 3, 2022, from prominent investors including Shenzhen Capital Group, Soochow Securities Co., Ltd., China Merchants Securities, and Wanrong Hongtu Fund. As a leader in the biotechnology, health care, and health and wellness industries, Suzhou Jimray Biotechnology is poised to make significant strides in the field of regenerative medicine.